Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $482.03, for a total value of $4,000,849.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $21,774,259.16. The trade was a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Trading Down 0.4%

NASDAQ UTHR traded down $1.78 on Thursday, reaching $490.24. 469,574 shares of the company were exchanged, compared to its average volume of 494,247. The business’s fifty day moving average price is $528.12 and its 200 day moving average price is $539.79. The stock has a market capitalization of $21.03 billion, a P/E ratio of 17.54, a price-to-earnings-growth ratio of 2.56 and a beta of 0.56. United Therapeutics Corporation has a fifty-two week low of $375.61 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same period last year, the company earned $6.41 EPS. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of UTHR. Amundi increased its position in shares of United Therapeutics by 48.4% during the second quarter. Amundi now owns 219,094 shares of the biotechnology company’s stock valued at $118,712,000 after acquiring an additional 71,495 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of United Therapeutics by 55,526.2% in the 2nd quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company’s stock worth $18,036,953,000 after acquiring an additional 33,229,108 shares during the last quarter. Wedmont Private Capital lifted its holdings in shares of United Therapeutics by 4.9% in the 2nd quarter. Wedmont Private Capital now owns 1,751 shares of the biotechnology company’s stock worth $958,000 after acquiring an additional 82 shares during the last quarter. Saudi Central Bank boosted its position in shares of United Therapeutics by 82.8% during the 2nd quarter. Saudi Central Bank now owns 2,761 shares of the biotechnology company’s stock worth $1,496,000 after purchasing an additional 1,251 shares during the period. Finally, AlphaGrep UK Ltd purchased a new position in shares of United Therapeutics during the 2nd quarter worth approximately $836,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on UTHR shares. JPMorgan Chase & Co. lifted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Bank of America reduced their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. Finally, Royal Bank Of Canada cut their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.